Migraine – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis – Acute Migraine (US)
Migraine is a neurological condition characterized by moderate to severe headaches of variable frequency that can be highly disabling and lower quality of life. Although triptans have long dominated the market for prescription antimigraine therapies, many patients only partially respond, or do not respond, to triptans. Other patients cannot tolerate these therapies or are ineligible to receive them owing to cardiovascular contraindications. As a result, a clear opportunity exists for therapeutic alternatives. Since 2020, new nontriptan products have increased competition in the acute migraine therapy market; these agents include improved formulations of established drugs such as Impel Pharmaceuticals’ Trudhesa and agents with novel mechanisms of action such as AbbVie’s Ubrelvy and Pfizer’s Nurtec ODT (oral CGRP receptor antagonists). With more launches expected through 2024, this quantitative analysis of national patient-level claims data examines the growing uptake of new brands to treat both newly diagnosed and recently treated patients in a market with many generic therapy options.
Questions answered
- What patient shares do key acute therapies and brands garner by line of therapy in newly diagnosed migraine patients? What are the quarterly trends in prescribing of acute therapies among recently treated and newly diagnosed migraine patients?
- How have oral CGRP receptor antagonists been integrated into the acute treatment algorithm, and what is their source of business?
- What percentage of migraine patients receive acute drug therapy within two years of diagnosis, and how quickly? What percentage of patients progress to later lines of acute therapy within two years of diagnosis?
- What percentage of migraine patients are treated with acute monotherapy vs. combination therapy? What are the most commonly used combinations?
- What are the product-level persistency rates for acute therapies among drug-treated patients?
Markets covered: United States.
Key companies: Pfizer, AbbVie, Eli Lilly, Scilex, Impel Pharmaceuticals, GlaxoSmithKline, Merck & Co.
Key drugs: Ubrelvy, Nurtec ODT, Reyvow, Elyxyb, Trudhesa, Zembrace SymTouch, Onzetra Xsail, sumatriptan, zolmitriptan, rizatriptan, and other FDA-approved acute antimigraine therapies
Product description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Solution enhancement
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and optional quarterly data refreshes.
Table of contents
- Migraine - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis - Acute Migraine (US)
- Treatment Algorithms CDA Migraine (Acute) US March 2023
- Treatment Algorithms CDA Migraine (Acute) 2023 Dashboard
Ankita Sharma, M.B.A., Manager, Healthcare Research & Data Analytics, CNS/Ophthalmology Disorders. Ankita’s focus is the epilepsy market. Prior to joining the company, she was a knowledge management manager at ZS Associates. She received her M.B.A. in hospital and healthcare administration from Symbiosis International University in India.
Andrea S. Witt, Ph.D., is Director of the Central Nervous System and Ophthalmology Disorders Portfolio at Clarivate, where she oversees a team of Business Insights Analysts and Senior Directors responsible for market research encompassing Neurology, Psychiatry, Pain, and Ophthalmology.
Her interests beyond specific CNS indications included the market potential for neuroprotectants and the impact of biomarkers on CNS markets. Dr. Witt’s research, analysis, and commentaries have appeared in Barron’s, Pharmaceutical Executive, PharmaVoice, Nature Medicine, and CNBC. Dr. Witt’s previous experience includes 10 years of scientific research conducted on neurodegenerative disorders at Harvard Medical School/Brigham and Women’s Hospital, Duke University, and the University of Texas-Southwestern Medical Center, where she earned her Ph.D. degree.